Therapies and surgical treatment of the posterior segment
- Tweets 3,851
- Following 433
- Followers 3,663
- Likes 616
👁️ What’s next for noninfectious uveitis treatment?
William R. Bloom, MD, and Ana M. Suelves, MD, PhD, explore advances in drug delivery, systemic immunomodulation and emerging targeted therapies.
🔗 Read more: ow.ly/l5pE50ZLfYr
#Uveitis #Retina
4
242
👁️ Does JIA-associated uveitis really end with childhood?
For many patients, inflammation, treatment dependence and ocular complications can continue into adulthood.
What should ophthalmologists know?
🔗 Read more: ow.ly/qcC950ZLQOt
#Uveitis #Retina
1
2
167
👁️ What can we learn from the LUGANO trial?
Jay S. Duker, MD, discusses the missed primary endpoint, treatment burden findings and what the results could mean for LUCIA and the Duravyu program.
▶️ Watch: ow.ly/u47w50ZHBGK
#WetAMD #Retina
206
🔬 Could a liquid biopsy reveal more about uveal melanoma?
Arun D. Singh, MD, and Kevin Allan, MD, PhD, explore how proteomics could support less-invasive diagnosis, prognostication and monitoring.
🔗 Read more: ow.ly/xHog50ZLfN3
#UvealMelanoma #Retina
3
239
📖 The September/October issue of Retinal Physician is here!
Explore advances in uveitis and ocular oncology, from proteomics and genetic testing to evolving treatments, radiation retinopathy prevention and more.
Read the latest issue 👇
ow.ly/qeQ850ZJsE8
#Retina
1
7
339
👁️ The FDA has accepted Nanoscope Therapeutics’ BLA for MCO-010, a one-time investigational gene therapy designed to restore visual function in people with retinitis pigmentosa, regardless of the underlying mutation.
🔗 Read more: ow.ly/I9wL50ZLeQz
#Ophthalmology
1
5
18
1,263
🧬 Could K8 offer a new approach to geographic atrophy?
Phase 2 data showed a 54% lower mean GA lesion growth rate at the best-performing dose, plus an encouraging visual acuity signal.
🔗 Read more: ow.ly/hHez50ZGyyq
#GeographicAtrophy #Retina
2
225
💧 Is a completely dry retina always the goal in nAMD?
Emerging evidence suggests that anatomic stability and minimizing fluid fluctuations may matter more than eliminating all retinal fluid.
🔗 Read more: ow.ly/UPfV50ZGy5l
#AMD #Retina #Ophthalmology
2
3
147
🧪 What did the ARCHER trial teach researchers about vision loss in geographic atrophy?
Margaret A. Chang, MD, MS, discusses key risk factors identified in phase 2 and how the findings helped shape the phase 3 ARCHER II study.
Watch in full▶️ ow.ly/X2lA50ZyWEz
#Retina
1
145
🧬 Could stem cell therapy help slow geographic atrophy?
Vivienne S. Hau, MD, PhD, discusses Phase 1b ASP7317 data showing a favorable safety profile and encouraging early findings in advanced GA.
▶️ Watch: ow.ly/L6t150ZALlO
#GeographicAtrophy #Retina #AMD
4
175
👓 The eyewear market is showing signs of stabilization.
The Vision Council’s Q2 2026 report highlights shifting consumer spending, including growth in $200+ eyewear purchases.
🔗 ow.ly/8YwJ50ZHBNq
#Eyewear #EyeCare
1
107
How well does your surgical documentation support your coding?
In the latest Coding Q&A, Elizabeth Cifers covers operative reports, medical necessity, diagnosis coding, and modifiers that can impact reimbursement.
Read more: ow.ly/G64e50Zncv4
#Retina #MedicalCoding
1
2
163
🎥 A closer look at the investigational PRIMA subretinal implant.
Dr. Frank Brodie demonstrates the surgical technique and discusses its potential for restoring central vision in patients with advanced geographic atrophy.
▶️ Watch: ow.ly/uC2X50ZtN5e
#Retina
1
154
👁️ Every complex case is an opportunity to learn.
Here, Nemo Patel walks through the management of a dislocated scleral-fixated IOL, sharing practical techniques for tackling one of vitreoretinal surgery's more challenging scenarios.
🔗 Watch here: ow.ly/OGtF50ZncMN
1
8
364
Retinal detachments in patients with uveitis require careful planning before, during, and after surgery.
In the latest Uveitis Corner, Dr. Sruthi Arepalli shares practical guidance on managing these complex cases.
Read more: ow.ly/macS50ZnbYY
#Retina #Uveitis
162
🧬 Could a smaller antibody format make a difference in retinal disease?
David A. Eichenbaum, MD, and Veeral S. Sheth, MD, discuss early JADE findings for OLN324 in nAMD and DME and why its 41 kDa design may matter.
🔗 ow.ly/R4pF50ZyXPV
#Retina #nAMD #DME
185
👁️ In neovascular AMD, is a completely dry retina always the goal?
Durga S. Borkar, MD, MMCi, explores why retinal fluid fluctuations and fluid type may matter more for long-term outcomes than residual fluid alone.
🔗 ow.ly/h4En50Zyto2
#Retina #AMD #Ophthalmology
1
188
🚨 BREAKING: Duravyu missed the primary endpoint in Phase 3 LUGANO for wet AMD, but reduced treatment burden by 42% vs aflibercept through week 56.
LUCIA results are expected in Q4 2026.
🔗 ow.ly/2clN50ZAv6E
#WetAMD #Retina #Ophthalmology
3
481
Intravitreal triamcinolone isn't just an anti-inflammatory.
In this article, John W. Kitchens explores how it can enhance vitreous visualization, facilitate vitrectomy, and support postoperative care.
Read more: ow.ly/vixJ50ZnbxX
#Vitrectomy #EyeSurgery #Ophthalmology
1
2
408
How should massive subretinal hemorrhage be managed?
Michael Y. Zhao and Harry W. Flynn Jr. present two long-term case reports and review the evidence supporting anti-VEGF monotherapy in selected patients.
Read more: ow.ly/IVGa50ZnbhS
#Retina #Ophthalmology #AntiVEGF
1
4
267